Connor, Clark & Lunn Investment Management Ltd.

Position in CYTK — Cytokinetics Inc

CIK 1596800 VANCOUVER, A1

Position in CYTK

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$294,075

-$1,382,424 QoQ

Shares Held

3,452

-88.7% QoQ

Ownership

0.002%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#344

of 477 holders

Holding Since

Dec 2021

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $650,455,383 across 105 Biotechnology names. CYTK ranks #86 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc.	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$294,075	3,452	-88.7%	Shares	Sole	2026-08-13
2025-09-30	$1,676,499	30,504	-38.7%	Shares	Sole	2025-11-13
2024-03-31	$3,489,374	49,770	-61.9%	Shares	Sole	2024-05-09
2023-12-31	$10,893,107	130,472	-22.3%	Shares	Sole	2024-02-09
2023-09-30	$4,948,602	167,977	+37.3%	Shares	Sole	2023-11-13
2023-06-30	$3,991,154	122,353	-27.0%	Shares	Sole	2023-08-10
2023-03-31	$5,897,210	167,582	+3.5%	Shares	Sole	2023-05-10
2022-12-31	$7,416,241	161,856	+151.8%	Shares	Sole	2023-02-10
2022-09-30	$3,114,559	64,284	-31.5%	Shares	Sole	2022-11-10
2022-06-30	$3,686,934	93,839	+12.7%	Shares	Sole	2022-08-05
2022-03-31	$3,064,984	83,265	-15.1%	Shares	Sole	2022-05-12
2021-12-31	$4,471,306	98,098	—	Shares	Sole	2022-02-10
No filing history on record for this holder in this stock.